Filing Flows › Verrica Pharmaceuticals (VRCA) › Q1 2026 › vs Q1 2025
Verrica Pharmaceuticals (VRCA) Q1 2026 vs Q1 2025 (year over year)
Verrica Pharmaceuticals's revenue rose $1.6M (+46%) from $3.4M in Q1 2025 to $5.0M in Q1 2026. The biggest changes: Product revenue, net +$868K (+25%); License and collaboration revenue +$716K (43×).
Verrica Pharmaceuticals, Q1 2026: revenue $5.0M (+46% year over year), operating margin -193.4%, net loss $9.7M, operating cash flow −$9.2M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $4.3M | $3.4M | $868K | +25% |
| License and collaboration revenue | $733K | $17K | $716K | 43× |
| Revenue | $5.0M | $3.4M | $1.6M | +46% |
| Other income, net | $33K | −$1.6M | $1.6M | — |
| Net loss | $9.7M | $9.7M | −$60K | -0.6% |
| Costs & expenses | $14.7M | $13.2M | $1.6M | +12% |
| Operating costs | $14.7M | $11.6M | $3.2M | +27% |
| Operating cash sources | $10.1M | $13.8M | −$3.7M | -27% |
| Depreciation | $17K | $52K | −$35K | -67% |
| Share-based compensation | $897K | $1.0M | −$129K | -13% |
| Cash used in operations | $9.2M | $12.7M | −$3.5M | -28% |
| Net loss absorbed | $9.7M | $9.7M | −$60K | -0.6% |
| Working capital & other | $395K | $4.0M | −$3.6M | -90% |
Questions
How much did Verrica Pharmaceuticals's revenue grow year over year in Q1 2026?
Verrica Pharmaceuticals's revenue rose $1.6M (+46%) from $3.4M in Q1 2025 to $5.0M in Q1 2026.
What drove Verrica Pharmaceuticals's revenue change in Q1 2026?
Product revenue, net +$868K (+25%); License and collaboration revenue +$716K (43×).